C
Choung U. Kim
Researcher at Bristol-Myers Squibb
Publications - 242
Citations - 5757
Choung U. Kim is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Neuraminidase & Phosphonate. The author has an hindex of 42, co-authored 242 publications receiving 5578 citations. Previous affiliations of Choung U. Kim include Academy of Sciences of the Czech Republic.
Papers
More filters
Journal ArticleDOI
Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA
Brian L. Robbins,R V Srinivas,Choung U. Kim,Norbert Bischofberger,Arnold Fridland,Arnold Fridland +5 more
TL;DR: Long persistence of PMPApp, particularly in resting lymphocytes, may be unique to the nucleoside phosphonate analogs and indicates that effective levels of the active metabolite can be achieved and maintained with relatively infrequent administration of the parent drug.
Journal ArticleDOI
Oral Administration of a Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071 Protects Mice and Ferrets against Influenza Infection
Dirk B. Mendel,Chun Y. Tai,Paul A. Escarpe,Weixing Li,Robert W. Sidwell,John H. Huffman,Clive Sweet,Kenneth J. Jakeman,James R. Merson,Steven A. Lacy,Willard Lew,Matthew A. Williams,Lijun Zhang,Ming S. Chen,Norbert Bischofberger,Choung U. Kim +15 more
TL;DR: The results indicate that GS 4104 is a novel, orally active antiviral agent with the potential to be used for the prophylaxis and treatment of influenza A and B virus infections.
Patent
Non nucleoside reverse transcriptase inhibitors
James M. Chen,Xiaowu Chen,Choung U. Kim,William A. Lee,Christopher P. Lee,Peter H. Nelson,James D. Tario,Lianhong Xu +7 more
TL;DR: Phosphorus-substituted imidazole compounds with anti-HIV properties having use as therapeutics and for other industrial purposes are disclosed in this article, where the compositions inhibit reverse transcriptase activity and are useful therapeutically for the inhibition of such enzymes, as well as in assays for the detection of these enzymes.
Journal ArticleDOI
Discovery and Development of GS 4104 (oseltamivir) An Orally Active Influenza Neuraminidase Inhibitor
TL;DR: The design, discovery, and development of oseltamivir as an oral therapeutic to treat influenza infection is summarized.
Journal ArticleDOI
Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071
Weixing Li,Paul A. Escarpe,Eugene J. Eisenberg,Kenneth C. Cundy,Clive Sweet,Kenneth J. Jakeman,James R. Merson,Willard Lew,Matthew A. Williams,Lijun Zhang,Choung U. Kim,Norbert Bischofberger,Ming S. Chen,Dirk B. Mendel +13 more
TL;DR: Results demonstrate that GS 4104 is an orally bioavailable prodrug of GS 4071 in animals and that it has the potential to be an oral agent for the prevention and treatment of influenza A and B virus infections in humans.